RxDoctor Payments Data

Alexey Ryskin, MD

Pain Medicine · Richland, WANPI 1366457236

Payments from drug & device makers

$755in general payments, 2019–2025

Across 37 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$280
  • Daiichi Sankyo Inc.$139
  • Abbott$87
  • Collegium Pharmaceutical, Inc.$86
  • Nevro Corp.$50
  • AbbVie$49
  • plus $64 from 3 others

What the payments were for

  • Food & beverage$755100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$755 in reported general payments places this provider in the 25th percentile of 124 pain medicine providers in Washington.

See all pain medicine providers in Washington

Medicare billing

Part B allowed, 2024
$2,362,787
Medicare patients
405
Services billed
21,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl21$11,059
Buprenorphine27$5,890
Xtampza ErOxycodone Myristate12$5,431
Oxycodone Hcl273$5,016
Naloxone Hcl71$4,788
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen153$4,170
Fentanyl26$3,835
Lidocaine19$2,807
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$2,450
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen79$2,277
Morphine Sulfate ErMorphine Sulfate50$1,470
Buprenorphine Hcl56$1,386
Methadone Hcl55$1,250
Hydromorphone Hcl61$1,088
Pregabalin46$846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$86$5,43112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 124 pain medicine providers in Washington.

Other pain medicine in Richland

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →